{"id":"dose-adaptation-of-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"1-5","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa. Dose adaptation refers to adjusting the enoxaparin dose based on patient factors such as renal function, body weight, and clinical indication to optimize anticoagulation efficacy while minimizing bleeding risk. This approach, as recommended by the French Cardiology Society, ensures therapeutic drug levels are maintained across diverse patient populations.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:28.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis and treatment"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT05672550","phase":"PHASE4","title":"Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-28","conditions":"Pediatric Kidney Transplant Recipients","enrollment":50},{"nctId":"NCT00412802","phase":"PHASE4","title":"Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"French Cardiology Society","startDate":"2006-12","conditions":"Acute Coronary Syndrome, Renal Failure","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"dose adaptation of Enoxaparin","genericName":"dose adaptation of Enoxaparin","companyName":"French Cardiology Society","companyId":"french-cardiology-society","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis and treatment, Acute coronary syndrome, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}